Tumor necrosis factor autoimmune diseases

Tumor necrosis factor-a (TNF-a) is a critical mediator of inflammation in autoimmune diseases like Crohn s disease and rheumatoid arthritis. Infliximab binds TNF-a and prevents its binding to the TNF receptor for treatment of these diseases. 

Tumor necrosis factor (TNF)—One of the cell-damaging proteins involved in inflammation, named because it appeared to kill cancer cells in the laboratory. Drugs for some autoimmune diseases like rheumatoid arthritis and Crohn s disease are designed to target TNF. 

Finally, antibodies such as adalimumab (Humira) and infliximab (Remicade) have been developed that bind directly to tumor necrosis factor alpha (TNF-alpha), thereby preventing this cytokine from causing damage to joints and other tissues. These anti-TNF-alpha drugs are therefore helpful in autoimmune diseases such as rheumatoid arthritis their pharmacology is addressed in more detail in Chapter 16. 

Recombinant human soluble tumor necrosis factor-alpha (TNF-a) receptor protein Enbrel (etanercept) Autoimmune diseases Amgen-Wyeth 4.5... 

Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P (2003) Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn s disease a prospective cohort study. Gastroenterology, 125 32-39. 

Tumor necrosis factor-a appears to play an important role in autoimmunity and inflammatory diseases. Which of the following is a humanized monoclonal antibody that binds to TNF-a and inhibits its action ... 

TNF-a Tumor necrosis factor alpha Inhibits tumor cells mediates immune response against bacterial infection induces septic shock, autoimmune diseases, rheumatoid arthritis, inflammation, and diabetes... 

Many of the chronic conditions — cardiovascular disease, diabetes, cancer, obesity, autoimmune diseases, rheumatoid arthritis, asthma, and depression — are associated with increased production of thromboxane Aj (TXAj), leukotriene 84 (LTB4), II ip, lL-6, tumor necrosis factor (TNF), and C-reactive protein. All these factors increase by increases in omega-6 fatty acid intake and decrease by increases in omega-3 fatty acid intake, either ALA or EPA and DHA. EPA and DHA are more potent, and most studies have been carried out using EPA and DHA. 

---